Modafinil for narcolepsy: Systematic review and meta-analysis

Case Reports and Clinical Practice Review

Volumn 16, Issue 8, 2010, Pages

  Golicki, Dominik ^a   Bala, Malgorzata M ^b,c   Niewada, Maciej ^a   Wierzbicka, Aleksandra ^d  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Polish Institute for Evidence Based Medicine   (Poland)

^d INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Meta analysis; Modafinil; Narcolepsy; Systematic review

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMITRIPTYLINE; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; MODAFINIL; OXYBATE SODIUM; PAROXETINE; PLACEBO; PROTRIPTYLINE; SERTRALINE; BENZHYDRYL DERIVATIVE; NEUROPROTECTIVE AGENT;

ARTICLE; BACKACHE; CATAPLEXY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DAYTIME SOMNOLENCE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRESS SYNDROME; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPEPSIA; EPWORTH SLEEPINESS SCALE; ERYTHEMA MULTIFORME; EVENING DOSAGE; FLU LIKE SYNDROME; HUMAN; INFECTION; INFORMATION RETRIEVAL; META ANALYSIS; NARCOLEPSY; NAUSEA; NERVOUSNESS; PAIN; PHARYNGITIS; QUALITY OF LIFE; QUESTIONNAIRE; REACTION TIME; RHINITIS; RISK REDUCTION; SHORT FORM 36; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; XEROSTOMIA; ADOLESCENT; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; REVIEW; TREATMENT OUTCOME; COCHRANE LIBRARY; COMPARATIVE STUDY; DATA BASE; DRUG FATALITY; EMBASE; MEDLINE; OUTCOME ASSESSMENT; SLEEP;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOLEPSY; NEUROPROTECTIVE AGENTS; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955339875     PISSN: 15076164     EISSN: 16433742     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Guilleminault C, Anagnos A. Narcolepsy: In: Kryger MH, Roth T, Dement WC (eds.), Principles and Practice of Sleep Medicine. 3. Philadelphia: WB Saunders Company, 2000: 676-86.
2. Lin JS, Hou Y, Jouvet M: Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci USA, 1996; 26: 14128-33.
3. Kumar R: Approved and investigational uses of modafinil: an evidencebased review. Drugs, 2008; 68: 1803-39.
4. Ballon JS, Feifel D: A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry, 2006; 67: 554-66.
5. Keam S, Walker MC: Therapies for narcolepsy with or without cataplexy: evidence-based review. Curr Opin Neurol, 2007; 20: 699-703.
6. Wise MS, Arand DL, Auger RR et al: Treatment of narcolepsy and other hypersomnias of central origin. Sleep, 2007; 30: 1712-27.
7. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep, 2007; 30: 1705-11.
8. Billiard M, Bassetti C, Dauvilliers Y et al: EFNS guidelines on management of narcolepsy. Eur J Neurol, 2006; 13: 1035-48.
9. Thorpy MJ: The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep, 1992; 15: 268-76.
10. Doghramji K, Mitler MM, Sangal RB et al: A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol, 1997; 103: 554-62.
11. Johns M: Rethinking the assessment of sleepiness. Sleep Med Rev, 1998; 2: 3-15
12. Stoddard RB, Goswami M, Ingalls K: The development and validation of an instrument to evaluate quality of life in narcolepsy subjects. Drug Inf J, 1996; 30: 850
13. Higgins JPT, Green S (eds.), Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org
14. Moher D, Cook DJ, Eastwood S et al: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet, 1999; 354: 1896-900.
15. Jadad AR, Moore RA, Carroll D et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996; 17: 1-12.
16. Besset A, Tafti M, Villemin E, Billiard M: [The effects of modafinil (300mg) on sleep, sleepiness and arousal in narcoleptic patients]. Neurophysiol Clin, 1993; 23: 47-60.
17. Beusterien KM, Rogers AE, Walsleben JA et al: Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep, 1999; 22: 757-65.
18. Billiard M, Besset A, Montplaisir J et al: Modafinil: a double-blind multicentric study. Sleep, 1994; 17: S107-12.
19. Black J, Houghton WC: Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep, 2006; 29: 939-46.
20. Boivin DB, Montplaisir J, Petit D et al: Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol, 1993; 16: 46-53.
21. Broughton RJ, Fleming JA, George CF et al: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology, 1997; 49: 444-51.
22. Moldofsky H, Broughton RJ, Hill JD: A randomized trial of the longterm, continued efficacy and safety of modafinil in narcolepsy. Sleep Med, 2000; 1: 109-16.
23. Saletu MT, Anderer P, Saletu-Zyhlarz GM et al: EEG-mapping differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil. Eur Arch Psychiatry Clin Neurosci, 2005; 255: 20-32.
24. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol, 1998; 43: 88-97
25. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology, 2000; 54: 1166-75.
26. Laffont F, Cathala HP, Waisbord P, Kohler F: Effects of modafinil on narcoleptic patients. Double-blind cross-over study. 9th European Congress of Sleep Research, Jerusalem, 1988; 215 (abstract)
27. st Annual Meeting of the Associated Professional Sleep Societes (9-14.06.2007, Minneapolis, Minesota). Abstract 0501. Sleep 2007; 30: A171
28. st Annual Meeting of the Associated Professional Sleep Societes (9-14.06.2007, Minneapolis, Minesota). Abstract 0647. Sleep 2007; 30: A219
29. th Congress of the European Sleep Research Society (12-16.09.2006, Innsbruck). Abstract P029. J Sleep Res, 2006; 15: 77
30. st Annual Meeting of the Associated Professional Sleep Societes (9-14.06.2007, Minneapolis, Minesota). Abstract 0655. Sleep 2007; 30: A222
31. Saletu M, Anderer P, Semlitsch HV et al: Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy. Psychiatry Res (Neuroimaging), 2007; 154: 69-84.
32. Food and Drug Administration. Center for Drug Evaluation and Research. FDA Drug Safety Newsletter. http://www.fda.gov/cder/dsn/2007_fall/postmarketing.htm#modafinil [accessed 4 Feb 2009]
33. Food and Drug Administration: Center for Drug Evaluation and Research. FDA Drug Safety Newsletter. http://www.fda.gov/cder/dsn/2007_fall/2007_fall.pdf [accessed 4 Feb 2009]
34. Vignatelli L, D'Alessandro R, Candelise L: Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev, 2005; 3: CD003724
35. Vignatelli L, Casmiro M, Lombardi C et al: Stimulant drugs for narcolepsy (Protocol). Cochrane Database Syst Rev, 2005; 4: CD005503